About
Research
Publications
2024
Ketamine induces multiple individually distinct whole-brain functional connectivity signatures
Moujaes F, Ji J, Rahmati M, Burt J, Schleifer C, Adkinson B, Savic A, Santamauro N, Tamayo Z, Diehl C, Kolobaric A, Flynn M, Rieser N, Fonteneau C, Camarro T, Xu J, Cho Y, Repovs G, Fineberg S, Morgan P, Seifritz E, Vollenweider F, Krystal J, Murray J, Preller K, Anticevic A. Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. ELife 2024, 13: e84173. PMID: 38629811, PMCID: PMC11023699, DOI: 10.7554/elife.84173.Peer-Reviewed Original ResearchConceptsResponse to ketamineAcute ketamineBehavioral effectsQuantified resting-state functional connectivityEffects of acute ketamineSymptom variationResting-state functional connectivityTreatment-resistant depressionFunctional connectivity signaturesGlobal brain connectivitySingle-subject levelInter-individual variabilityPlacebo-controlled studyFunctional connectivityConnectivity signaturesBrain connectivityHealthy participantsSingle-blind placebo-controlled studyNeural variationsTreatment conditionsKetamineGene expression targetsPharmacological biomarkersPilot awardParvalbumin
2023
511. Common and Distinct Effects of Incentives on Spatial Working Memory in Schizophrenia and Obsessive-Compulsive Disorder
Sarantopoulos C, Shin D, Schleifer C, Moujaes F, Adkinson B, Ji J, Kolabaric A, Flynn M, Santamauro N, Krystal J, Murray J, Repovs G, Martin W, Pittenger C, Anticevic A, Cho Y. 511. Common and Distinct Effects of Incentives on Spatial Working Memory in Schizophrenia and Obsessive-Compulsive Disorder. Biological Psychiatry 2023, 93: s300-s301. DOI: 10.1016/j.biopsych.2023.02.751.Peer-Reviewed Original Research523. Analyzing Temporal Stability of Working Memory Deficits in Early-Course Psychosis Spectrum Disorders
Schutte C, Rahmati M, Fonteneau C, Fram G, Schleifer C, Adkinson B, Kolabaric A, Hill N, Santamauro N, Murray J, Repovš G, Cho Y, Anticevic A. 523. Analyzing Temporal Stability of Working Memory Deficits in Early-Course Psychosis Spectrum Disorders. Biological Psychiatry 2023, 93: s305-s306. DOI: 10.1016/j.biopsych.2023.02.763.Peer-Reviewed Original Research248. Effects of NMDA Receptor Antagonist Ketamine on Neural Tuning
Rahmati M, Moujaes F, Schleifer C, Ji J, Fonteneau C, Tamayo Z, Santamauro N, Respov G, Fineberg S, Krystal J, Murray J, Cho Y, Anticevic A. 248. Effects of NMDA Receptor Antagonist Ketamine on Neural Tuning. Biological Psychiatry 2023, 93: s193-s194. DOI: 10.1016/j.biopsych.2023.02.488.Peer-Reviewed Original Research
2022
Illness Phase as a Key Assessment and Intervention Window for Psychosis
Kohler C, Wolf D, Abi-Dargham A, Anticevic A, Cho Y, Fonteneau C, Gil R, Girgis R, Gray D, Grinband J, Javitch J, Kantrowitz J, Krystal J, Lieberman J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Group T, D'Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gur R, Gur R, Calkins M. Illness Phase as a Key Assessment and Intervention Window for Psychosis. Biological Psychiatry Global Open Science 2022, 3: 340-350. PMID: 37519466, PMCID: PMC10382701, DOI: 10.1016/j.bpsgos.2022.05.009.Peer-Reviewed Original ResearchIllness phasePotential critical windowsPhase-specific biomarkersDopaminergic abnormalitiesFunctional outcomeSpecialty careSymptom assessmentIllness stageChronic illnessClinical assessmentIllness trajectoryNeurophysiological biomarkersFunctional abnormalitiesClinical careEarly psychosisMemory dysfunctionPsychotic disordersTreatment targetsAllostatic adaptationIntervention windowClinical programsBrain developmentCritical windowDysfunctionIllnessReward and loss incentives improve spatial working memory by shaping trial-by-trial posterior frontoparietal signals
Cho YT, Moujaes F, Schleifer CH, Starc M, Ji JL, Santamauro N, Adkinson B, Kolobaric A, Flynn M, Krystal JH, Murray JD, Repovs G, Anticevic A. Reward and loss incentives improve spatial working memory by shaping trial-by-trial posterior frontoparietal signals. NeuroImage 2022, 254: 119139. PMID: 35346841, PMCID: PMC9264479, DOI: 10.1016/j.neuroimage.2022.119139.Peer-Reviewed Original ResearchConceptsMemory precisionSpatial working memoryIntraparietal sulcusPrecentral sulcusWorking memoryMotivational signalsBOLD signalParietal cortexReward/lossVisual association regionsDorsolateral prefrontal cortexGoal-directed activityMemory paradigmMemory performanceMemory processesAnterior parietal cortexExecutive networkNeural changesSensory processesPrefrontal cortexLoss incentivesVentral striatumNon-human primate studiesTranslational neuroscienceMemory
2021
Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia
Abi-Dargham A, Javitch JA, Slifstein M, Anticevic A, Calkins ME, Cho YT, Fonteneau C, Gil R, Girgis R, Gur RE, Gur RC, Grinband J, Kantrowitz J, Kohler C, Krystal J, Murray J, Ranganathan M, Santamauro N, Van Snellenberg J, Tamayo Z, Wolf D, D’Souza D, Srihari V, Gueorguieva R, Patel P, Forselius-Bielen K, Lu J, Butler A, Fram G, Afriyie-Agyemang Y, Selloni A, Cadavid L, Gomez-Luna S, Gupta A, Radhakrishnan R, Rashid A, Aker R, Abrahim P, Nia A, Surti T, Kegeles L, Carlson M, Goldberg T, Gangwisch J, Benedict E, Govil P, Brazis S, Mayer M, de la Garrigue N, Fallon N, Baumvoll T, Abeykoon S, Perlman G, Bobchin K, Elliott M, Schmidt L, Rush S, Port A, Heffernan Z, Laney N, Kantor J, Hohing T, Gray D, Lieberman J. Dopamine D1R Receptor Stimulation as a Mechanistic Pro-cognitive Target for Schizophrenia. Schizophrenia Bulletin 2021, 48: 199-210. PMID: 34423843, PMCID: PMC8781338, DOI: 10.1093/schbul/sbab095.Peer-Reviewed Original ResearchConceptsCortical dopamine neurotransmissionPositive allosteric modulationImportant therapeutic targetPF-06412562Dopaminergic receptorsD1R stimulationDA levelsTolerable dosesLevel of stimulationDopamine neurotransmissionReceptor stimulationTherapeutic targetPartial agonistCognitive deficitsBiased agonismFull agonismTarget engagementAllosteric modulationNew drugsStimulationPoor bioavailabilitySchizophreniaOptimal stimulationDrugsExpression levels
2020
P.499 Ketamine's influence on global resting-state functional connectivity and individual variation in neuro-behavioural relationships
Moujaes F, Preller K, Vollenweider F, Schleifer C, Adkinson B, Kolobaric A, Fineberg S, Krystal J, Repovs G, Santamauro N, Morgan P, Savic A, Cho Y, D. M, Anticevic A. P.499 Ketamine's influence on global resting-state functional connectivity and individual variation in neuro-behavioural relationships. European Neuropsychopharmacology 2020, 40: s278-s279. DOI: 10.1016/j.euroneuro.2020.09.363.Peer-Reviewed Original Research
2019
S159. NMDA Receptor Antagonism Effects on Delayed Spatial Working Memory and Distraction in Comparison With Schizophrenia
Moujaes F, Preller K, Vollenweider F, Schleifer C, Ji J, Adkinson B, Kolobaric A, Flynn M, Fineberg S, Krystal J, Repovs G, Santamauro N, Morgan P, Savic A, Cho Y, Murray J, Anticevic A. S159. NMDA Receptor Antagonism Effects on Delayed Spatial Working Memory and Distraction in Comparison With Schizophrenia. Biological Psychiatry 2019, 85: s358. DOI: 10.1016/j.biopsych.2019.03.910.Peer-Reviewed Original ResearchF195. NMDAR Antagonism via Ketamine Differentially Modulates Thalamic Versus Hippocampal Brain-Wide Functional Connectivity
Moujaes F, Schleifer C, Ji L, Adkinson B, Kolobaric A, Flynn M, Fineberg S, Krystal J, Repovs G, Cho Y, Santamauro N, Morgan P, Savic A, Murray J, Anticevic A. F195. NMDAR Antagonism via Ketamine Differentially Modulates Thalamic Versus Hippocampal Brain-Wide Functional Connectivity. Biological Psychiatry 2019, 85: s289. DOI: 10.1016/j.biopsych.2019.03.732.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Biomarkers of Clinical Subtype and Treatment Response in Obsessive-Compulsive Disorder
HIC ID0803003626RoleSub InvestigatorPrimary Completion Date04/19/2025Recruiting ParticipantsGenderBothAge18 years - 70 years
News
Get In Touch
Contacts
Locations
Temple Medical Center
Lab
40 Temple Street, Ste 6D
New Haven, CT 06510